HAE Stock Analysis: Buy, Sell, or Hold?
HAE - Haemonetics Corporation
$108.80
0.58 (0.54%)
▲
5d:
+19.82%
30d:
+40.57%
90d:
+75.65%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When HAE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: HAE is 17.7% above its trading range ($92.47). Market expects 15.6% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: HAE is 17.7% above its trading range ($92.47). Market expects 15.6% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$91.95
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$57.10
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HAE is currently trading at $108.80, which is considered extended relative to its 30-day fair value range of $76.91 to $92.47. From a valuation perspective, the stock is trading at a premium (Forward PE: 20.6) compared to its historical average (13.3). At these levels, the market is pricing in 15.6% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, HAE is in a strong uptrend. The price is approaching resistance at $109.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HAE scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HAE is in a strong uptrend. The price is approaching resistance at $109.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HAE scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$76.91 -
$92.47
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
9.5%
All Signals
- BEARISH: Price significantly overextended (+17.7% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($104.10)
- BEARISH: Market expects 15.6% growth - appears too optimistic based on history
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$76.91 -
$92.47
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$85.97
Resistance Level
$109.57
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.56
Wall Street Target
$104.10
(-4.3%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
2.9%
Profit Margin
7.1%
Valuation Premium vs History
+15.6% premium
PE vs Historical
20.6 vs 13.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+15.6%
(market-implied from PE analysis)
1-Year Target
$125.77
(+16%)
2-Year Target
$145.39
(+34%)
3-Year Target
$168.07
(+55%)
3-Yr Target (if PE normalizes)
(PE: 21→13)
PE COMPRESSION
$108.72
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: 7.0%)
$133.44
(+23%)
Base:
(SPY PE: 20.1, Growth: 7.0%)
$130.25
(+20%)
Bear:
(PE: 13.3, Growth: 7.0%)
$86.31
(-21%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (21x PE) as earnings recover.
Forward PE: 20.62 | Forward EPS (Implied): $5.28
Bull Case
$131.38
(+21%)
Analyst growth 15.0%, PE expands to 21.7
Base Case
$108.80
(0%)
Market implied 0.0%, PE stable at 20.6
Bear Case
$83.23
(-24%)
Severe decline -15.0%, PE contracts to 18.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 22, 2026 1:54 PM ET
Data refreshes hourly during market hours. Next update: 2:54 PM
Data refreshes hourly during market hours. Next update: 2:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HAE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 35 SELL |
